Heike Peterziel

This study compares ex vivo short-term, organoid, and PDX drug screening methods in neuroblastoma, finding ex vivo screens are faster and more consistent with in vivo results.

This study develops an ex vivo drug sensitivity testing platform for rare solid tumors and finds that high in vitro sensitivity correlates with clinical benefit and progression-free survival.

This study identifies GLRX3 as a vulnerability in Ewing sarcoma driven by EWSR1::FLI1 fusion oncoproteins, showing its role in oxidative stress and iron homeostasis and potential therapeutic targeting.